EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOKIG00005035497
Gene Symbol: NR3C1
3 Cross references
198 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSOKIG00005050038
Gene Symbol: NR3C1
3 Cross references
199 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSOKIG00005033418
Gene Symbol: NR3C1
1 Cross references
200 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSOKIG00005027272
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOKIG00005014230
Gene Symbol: OPRK1
1 Cross references
192 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOKIG00005046038
Gene Symbol: OPRK1
3 Cross references
192 Possible Orthologues:

Opioid Receptor, Kappa 1

Ensembl ID : ENSOKIG00005033536
Gene Symbol: OPRK1
1 Cross references
197 Possible Orthologues:

Oxysterols Receptor Lxr-Alpha-Like

Ensembl ID : ENSOKIG00005005982
Gene Symbol: LOC109885055
3 Cross references
384 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOKIG00005027133
Gene Symbol: OXTR
3 Cross references
177 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOKIG00005001525
Gene Symbol: OXTR
3 Cross references
177 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOKIG00005035316
Gene Symbol: PTH1R
1 Cross references
190 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOKIG00005046578
Gene Symbol: PTH1R
1 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).